Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 314

The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

Open access
Cavo, Michele, Rajkumar, S. Vincent, Palumbo, Antonio, Moreau, Philippe, Orlowski, Robert, Bladé, Joan, Sezer, Orhan, Ludwig, Heinz, Dimopoulos, Meletios A., Attal, Michel, Sonneveld, Pieter, Boccadoro, Mario, Anderson, Kenneth C., Richardson, Paul G., Bensinger, William, Johnsen, Hans E., Kroeger, Nicolaus, Gahrton, Gösta, Bergsagel, P. Leif, Vesole, David H., Einsele, Hermann, Jagannath, Sundar, Niesvizky, Ruben, Durie, Brian G. M., San Miguel, Jesus, Lonial, Sagar·2011·Blood

Abstract

The role of high-dose therapy followed by autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) continues to evolve in the novel agent era. The choice of induction therapy has moved from conventional chemotherapy to newer regimens incorporating the immunomodulatory derivatives thalidomide or lenalidomide and the proteasome inhibitor bortezomib. These drugs combine well with traditional therapies and with one another to form various doublet, triplet, and quadruplet regimens. Up-front use of these induction treatments, in particular 3-drug combinations, has affected unprecedented rates of complete response that rival those previously seen with conventional chemotherapy and subsequent ASCT. Autotransplantation applied after novel-agent-based induction regimens provides further improvement in the depth of response, a gain that translates into extended progression-free survival and, potentially, overall survival. High activity shown by immunomodulatory derivatives and bortezomib before ASCT has recently led to their use as consolidation and maintenance therapies after autotransplantation. Novel agents and ASCT are complementary treatment strategies for MM. This article reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of younger, transplantation-eligible MM patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-02-297325

Cites

104 of 104 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 104 references

Cited by

See all 314

Metadata

Authors
Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., Sezer, O., Ludwig, H., Dimopoulos, M. A., Attal, M., Sonneveld, P., Boccadoro, M., Anderson, K. C., Richardson, P. G., Bensinger, W., Johnsen, H. E., Kroeger, N., Gahrton, G., Bergsagel, P. L., Vesole, D. H., Einsele, H., Jagannath, S., Niesvizky, R., Durie, B. G. M., San Miguel, J., & Lonial, S.
Venue
Blood
Published
2011-06-09
Volume
117
Issue
23
Pages
6063-6073
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2114396320
Cited by
314
References
104
FWCI
21.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. https://app.cochat.ai/papers/10.1182/blood-2011-02-297325
The paper
Cavo, M., Rajkumar, S. V., Palumbo, A., Moreau, P., Orlowski, R., Bladé, J., Sezer, O., Ludwig, H., Dimopoulos, M. A., Attal, M., Sonneveld, P., Boccadoro, M., Anderson, K. C., Richardson, P. G., Bensinger, W., Johnsen, H. E., Kroeger, N., Gahrton, G., Bergsagel, P. L., . . . Lonial, S. (2011). International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. https://doi.org/10.1182/blood-2011-02-297325

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.